Stay updated with breaking news from Lenalidomide Refractory Multiple. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Media contact: Investor contact: ...
The indication is for adult patients with multiple myeloma who are refractory to lenalidomide and have previously received at least 1 line of therapy.
The application is supported by the Phase 3 CARTITUDE-4 study, which showed significant improvement in primary endpoint of progression-free survival compared to standard regimens CARTITUDE-4 is the... | June 6, 2023
At 16 months median follow-up, cilta-cel significantly improved progression-free survival compared to two standard of care treatment regimens1 ...